Kidney function and markers of renal damage after renal denervation. Does method of measurement matter? The Reshape CV‐Risk Study

Solbu, Marit Dahl; Miroslawska, Atena; Norvik, Jon Viljar; Eriksen, Bjørn Odvar; Steigen, Terje K.

doi:10.1111/jch.14214

Cited by 7 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the cohort presented here, no adverse effects on renal function were found as a safety aspect in patients both without and with renal insufficiency (eGFR < 60 ml/min/1.7 m 2 ). This finding is consistent with that of other reports demonstrating this over a FU period of 12 (30), 24 (31), and 36 (17) months. At the long-term FU, a decline in renal function was found in both groups, as expected, in the range of 0.9-5.8 ml/min/ 1.73 m 2 annually reported for hypertensive patients (32,33).…”

Section: Discussionsupporting

confidence: 94%

Safety and efficacy of renal sympathetic denervation: a 9-year long-term follow-up of 24-hour ambulatory blood pressure measurements

Vogt

Dutzmann

Nußbaum

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundRenal sympathetic denervation (RDN) has been shown to lower arterial blood pressure both in the presence and in the absence of antihypertensive medication in an observation period of up to 3 years. However, long-term results beyond 3 years are scarcely reported.MethodsWe performed a long-term follow-up on patients who were previously enrolled in a local renal denervation registry and who underwent radiofrequency RDN with the Symplicity Flex® renal denervation system between 2011 and 2014. The patients were assessed to evaluate their renal function by performing 24-hour ambulatory blood pressure measurement (ABPM), recording their medical history, and conducting laboratory tests.ResultsAmbulatory blood pressure readings for 24 h were available for 72 patients at long-term follow-up (FU) [9.3 years (IQR: 8.5–10.1)]. We found a significant reduction of ABP from 150.1/86.1 ± 16.9/12.0 mmHg at baseline to 138.3/77.1 ± 16.5/11.1 mmHg at long-term FU (P < 0.001 for both systolic and diastolic ABP). The number of antihypertensive medications used by the patients significantly decreased from 5.4 ± 1.5 at baseline to 4.8 ± 1.6 at long-term FU (P < 0.01). Renal function showed a significant but expected age-associated decrease in the eGFR from 87.8 (IQR: 81.0–100.0) to 72.5 (IQR: 55.8–86.8) ml/min/1.73 m2 (P < 0.01) in patients with an initial eGFR > 60 ml/min/1.73 m2, while a non-significant decrease was observed in patients with an initial eGFR < 60 ml/min/1.73 m2 at long-term FU [56.0 (IQR: 40.9–58.4) vs. 39.0 (IQR: 13.5–56.3) ml/min/1.73 m2].ConclusionsRDN was accompanied by a long-lasting reduction in blood pressure with a concomitant reduction in antihypertensive medication. No negative effects could be detected, especially with regard to renal function.

show abstract

Section: Discussionsupporting

confidence: 94%

Safety and efficacy of renal sympathetic denervation: a 9-year long-term follow-up of 24-hour ambulatory blood pressure measurements

Vogt

Dutzmann

Nußbaum

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Even though patients without CKD had a greater decrease in eGFR during the first year after RDN, there was no significant difference in the decline of eGFR between the two groups after three years of follow-up. 56 The 3-year incidence of CV death (not non-CV) and all CV and renal events was significantly higher after RDN in patients with CKD than in those without CKD, while the incidence of renal artery reintervention due to perforation or dissection and vascular complications was low in both groups without a significant difference in frequency between the studied groups. 57 However, due to the design of the registry and the absence of a sham control group (placebo), it is not possible to assess whether RDN reduces the frequency of CV events in patients with CKD through BP-dependent and BP-independent mechanisms.…”

Section: Renal Denervation In Ckd Patientsmentioning

confidence: 81%

“…62 Conversely, in non-randomized studies in which renal function (GFR) was directly measured (mGFR) and not estimated (eGFR), impairment of renal function was observed even 1-2 years after RDN. 56 Therefore, more long-term data with mGFR are needed to conclude on the renal safety of RDN in this population like currently ongoing RDN-CKD Study Which aimed to demonstrate that RDN effectively reduces 24-h ambulatory BP in 80 patients with CKD stage 3A or 3B. 63…”

mentioning

confidence: 99%

Renal Denervation in the Treatment of Resistant Hypertension and Difficult-to-Control Hypertension – Consensus Document of the Croatian Hypertension League – Croatian Society of Hypertension, Croatian Cardiac Society, Croatian Endovascular Initiative, Croatian Society for Diabetes and Metabolic Diseases, Croatian Renal Association, and Croatian Society of Family Physicians of the Croatian Medical Association

Jelaković,

Perkov,

Barišić

et al. 2023

VHRM

View full text Add to dashboard Cite

Renal denervation (RDN) as a method of treating arterial hypertension (AH) was introduced in Croatia in 2012. A multidisciplinary team and a network of hospitals that diagnose and treat patients with severe forms of AH were established, and a very strict diagnostic-treatment algorithm was prepared. At monthly meetings patients with truly resistant hypertension who were candidates for RDN were discussed. According to the 2021 ESH position statement and 2023 ESH guidelines, RDN is considered an alternative and additional, not a competitive method of treating patients with various forms of AH which must be performed by following a structured procedure and the patient's preference should be considered. In view of the changes in the global scientific community, the Croatian Hypertension League brings this consensus document on RDN conducted with radiofrequency-based catheter, the only currently available method in Croatia. In this document, exclusion and inclusion criteria are shown, as well as three groups of patients in whom RDN could be considered. The new diagnostic-treatment algorithm is prepared and follow-up procedure is explained. In Croatia, RDN is reimbursed by the national insurance company, thus pharmacoeconomic analyses is also shown. Criteria required by an individual centre to be approved of RDN are listed, and plans for prospective research on RDN in Croatia, including the Croatian registry for RDN, are discussed.

show abstract

Effects of renal denervation on the kidney: albuminuria, proteinuria, and renal function

Yamazaki,

Konishi,

Kitada

2024

Hypertens Res

View full text Add to dashboard Cite

Kidney function and markers of renal damage after renal denervation. Does method of measurement matter? The Reshape CV‐Risk Study

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cited by 7 publications

References 47 publications

Safety and efficacy of renal sympathetic denervation: a 9-year long-term follow-up of 24-hour ambulatory blood pressure measurements

Safety and efficacy of renal sympathetic denervation: a 9-year long-term follow-up of 24-hour ambulatory blood pressure measurements

Effects of renal denervation on the kidney: albuminuria, proteinuria, and renal function

Contact Info

Product

Resources

About